RESUMO
PURPOSE: Endothelial dysfunction and inflammation are conditions which fuel atherosclerosis and ischaemic heart disease. We have previously reported reduced cardiovascular (CV) mortality following supplementation with selenium and coenzyme Q10 to 443 elderly individuals with low selenium status (mean 67 µg/L) for 4 years. Here, we wanted to evaluate a possible association between the supplementation and the plasma concentrations of the von Willebrand factor (vWf), and the plasminogen activator inhibitor-1 (PAI-1), as they, besides other functions, are also strongly associated with endothelial function. METHODS: In this sub-study, 308 individuals (active substance: 157, placebo: 151) were included. Blood samples were drawn after 6 and 36 months and vWf and PAI-1 were determined in plasma by ELISA. Changes in concentrations of the biomarkers were evaluated by the use of T tests, repeated measures of variance, and ANCOVA analyses. RESULTS: The active treatment group presented a lower level of vWf after 36 months compared with the placebo group (1.08 U/mL vs. 5.10 U/mL; p = 0.0007). The results were validated through the repeated measures of variance evaluation. The PAI-1 levels showed an equally significant decrease in the active group (26.2 ng/mL vs. 49.2 ng/mL; p = 0.0002) and were also validated through repeated measures of variance evaluation. CONCLUSION: In this sub-study on elderly receiving selenium and coenzyme Q10, or placebo we found significantly lower levels of vWf and PAI-1 in the active treatment group as compared to the placebo group. We interpret this as a better endothelial function because of the intervention, which accords with a previous finding of reduced CV mortality.
Assuntos
Doenças Cardiovasculares , Selênio , Idoso , Suplementos Nutricionais , Humanos , Inibidor 1 de Ativador de Plasminogênio , Estudos Prospectivos , Ativador de Plasminogênio Tecidual , Ubiquinona/análogos & derivados , Fator de von WillebrandRESUMO
The aims of this study were to compare circulating cytokines between FM and healthy controls and to investigate the effect on cytokine levels by 15 weeks of progressive resistance exercise or relaxation therapy in FM. Baseline plasma cytokine levels and clinical data were analyzed in 125 women with FM and 130 age-matched healthy women. The FM women were then randomized to progressive resistance exercise (n = 49) or relaxation (n = 43). Baseline IL-2, IL-6, TNF-α, IP-10, and eotaxin were higher in FM than in healthy controls (P < 0.041), whereas IL-1ß was lower (P < 0.001). There were weak correlations between cytokine levels and clinical variables. After both interventions, IL-1ra had increased (P = 0.004), while IL-1ß had increased in the relaxation group (P = 0.002). Changes of IFN-γ, IL-2, IL-4, IL-6, IL-8, and IL-17A were weakly correlated with changes of PPT, but there were no significant correlations between changes of cytokine and changes in other clinical variables. The elevated plasma levels of several cytokines supports the hypothesis that chronic systemic inflammation may underlie the pathophysiology of FM even if the relation to clinical variables was weak. However, 15 weeks of resistance exercise, as performed in this study, did not show any anti-inflammatory effect on neither FM symptoms nor clinical and functional variables. This trial is registered with ClinicalTrials.gov NCT01226784, registered October 21, 2010. The first patient was recruited October 28, 2010.
Assuntos
Citocinas/sangue , Fibromialgia/sangue , Fibromialgia/terapia , Terapia de Relaxamento/métodos , Treinamento Resistido/métodos , Adulto , Exercício Físico/fisiologia , Feminino , Fibromialgia/imunologia , Humanos , Inflamação/sangue , Inflamação/imunologia , Inflamação/terapia , Interleucina-17/sangue , Interleucina-1beta/sangue , Interleucina-2/sangue , Interleucina-4/sangue , Interleucina-6/sangue , Interleucina-8/sangue , Pessoa de Meia-Idade , Fator de Necrose Tumoral alfa/sangueRESUMO
The aim of this study is to evaluate possible benefits of hyperbaric oxygen (HBO) therapy in the treatment of deep postoperative infections in six high risk paediatric patients with neuromuscular spine deformity. The study involved review of medical records including radiology, office visits, and telephone contacts for six patients, referred for postoperative HBO therapy in 2003-2005. Infection control and healing without removal of implants or major revision surgery with a minimum of 2-year follow-up after index surgery were considered to represent success. All infections were resolved. Median time for wound healing, normalisation of blood tests and antibiotic weaning were 3 months. Radiological bony fusion, intact implants without any signs of radiolucent zones were seen in all cases at a mean follow-up of 54 months (37-72). Side effects of HBO treatment were minor. HBO is a safe and potentially useful adjuvance in the treatment of early deep postoperative infections in complex situations with spinal implants in high risk paediatric patients.
Assuntos
Infecções Bacterianas/terapia , Coluna Vertebral/cirurgia , Infecção da Ferida Cirúrgica/terapia , Adolescente , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Oxigenoterapia Hiperbárica , Lactente , Masculino , Resultado do Tratamento , CicatrizaçãoRESUMO
To evaluate non-chemical strategies to control pasture-borne parasites in first-season grazing (FSG) cattle, a 3-year grazing trial was conducted during 2002-2004 on naturally infected pastures on a commercial beef cattle farm in Sweden. A uniform pasture was divided in 4 equal 2 ha paddocks onto each of which 10, 5-9 months old dairy breed steer calves were allocated at turn-out in May each year. Two strategies were evaluated: (1) turn-out onto pasture which had been grazed the previous year by second-season grazing (SSG) steers, followed by a move to aftermath in mid-July (RT) and (2) supplementation with concentrate and roughage for 4 weeks from turn-out (FD). Comparisons were made with an untreated (UT), and an anthelmintic treated control group (DO). Animal parasitology and performance were monitored monthly throughout the 20 weeks grazing period. Additional sampling occasions were performed on day 9 (for coccidia) and 10 weeks after turn-out (mid-July). Due to clinical parasitic gastro-enteritis (PGE), salvage treatments were performed on all animals in group FD approximately 7 weeks after turn-out in 2003 and of three animals in group UT 5 weeks after turn-out in 2004. In 2003, the geometric mean oocyst excretion 9 days after turn-out was approximately 150,000 opg of mainly Eimeria alabamensis in group FD, and in 2004 approximately 180,000 opg in group UT. Apart from the DO group, geometric mean faecal egg counts (FEC) were between 80 and 400 epg 4 weeks after turn-out. Mean serum pepsinogen concentrations (SPC) of approximately 3.6 U tyrosine were recorded in the FD and UT groups from late August 2002. In 2003 and 2004, mean concentrations in these groups were between 4.1 and 7.2 U tyrosine 8 weeks after turn-out. By the end of the three grazing seasons the average weight gain difference compared to the DO group was for FD -29, -38 and -5 kg and for RT -4, -21 and +14 kg, and compared to the UT group -18, +2 and +22 for FD and +7, +19 and +41 kg for group RT. In conclusion, the rotation control strategy showed promising results, whereas the strategic feeding was poor from a parasite control standpoint.
Assuntos
Doenças dos Bovinos/prevenção & controle , Doenças dos Bovinos/parasitologia , Coccidiose/veterinária , Indústria de Laticínios/métodos , Infecções por Nematoides/veterinária , Animais , Anti-Helmínticos/administração & dosagem , Anti-Helmínticos/farmacologia , Anticorpos Anti-Helmínticos/sangue , Anticorpos Antiprotozoários/sangue , Bovinos , Coccidiose/imunologia , Coccidiose/prevenção & controle , Suplementos Nutricionais , Eimeria/isolamento & purificação , Fezes/parasitologia , Ivermectina/administração & dosagem , Ivermectina/análogos & derivados , Ivermectina/farmacologia , Masculino , Nematoides/isolamento & purificação , Infecções por Nematoides/imunologia , Infecções por Nematoides/prevenção & controle , Contagem de Ovos de Parasitas/veterinária , Pepsinogênio A/sangue , Distribuição Aleatória , Fatores de Tempo , Aumento de Peso/fisiologiaRESUMO
OBJECTIVES: X-ray fluorescence (XRF) is a non-invasive method for determining the iodine content of the thyroid gland in vivo. In spite of the obvious clinical value of such a method in situations of iodine deficiency or iodine overload, the method has not so far been widely used. The objective was to investigate the applicability of the XRF method in a larger number of subjects. DESIGN AND SUBJECTS: The study comprised 37 individuals, aged 60-65 years, who had spent their entire life with iodine supplementation through iodinated table salt. Individuals with (previous) thyroid disease were excluded. The individual thyroid function had previously been evaluated by measurements of thyroid-related hormones, thyroid volume and 131-Iodine (131I) uptake which indicated a sufficient iodine intake of the population in the area. Iodine in the right thyroid lobe in each subject was examined using XRF. RESULTS: The mean thyroid iodine concentration was 0.4 mg mL(-1), corresponding to a mean total iodine content of 5.2 mg (range 0.9-20.2). There was a pronounced difference between individuals. No correlation was found between iodine concentration and 131I uptake or thyroid volume. Neither was iodine content and 131I uptake correlated. CONCLUSIONS: In a population living under iodine-sufficient conditions, a large variation of iodine stored in the thyroid is compatible with euthyroidism. Determination of the iodine pool by XRF investigation is feasible in a clinical setting and the method offers a unique possibility to study the intrathyroidal iodine pool in subjects with thyroid disease. The low radiation dose enables the use of the method in pregnant women and also in young individuals.
Assuntos
Iodo/análise , Glândula Tireoide/química , Idoso , Suplementos Nutricionais , Estudos de Viabilidade , Feminino , Humanos , Iodo/administração & dosagem , Iodo/urina , Radioisótopos do Iodo/farmacocinética , Masculino , Pessoa de Meia-Idade , Valores de Referência , Cloreto de Sódio na Dieta/administração & dosagem , Espectrometria por Raios X/métodos , Glândula Tireoide/anatomia & histologiaRESUMO
PURPOSE: Human septic shock can be replicated in the endotoxaemic pig. Endotoxaemia causes a multitude of events, including reduced PaO(2) and increased lipid peroxidation. This study was designed to evaluate the possible effects of a commonly used anaesthetic drug with known antioxidant properties (propofol) during porcine endotoxaemia. METHODS: Ten pigs were anaesthetised and given a 6 h E. coli endotoxin infusion. The animals received, randomly, a supplementary continuous infusion of propofol emulsion (containing 0.005% EDTA) or the corresponding volume of vehicle (controls). Pathophysiologic responses were determined. Non-enzymatic (by measuring plasma 8-iso-PGF(2 alpha) and enzymatic (by measuring plasma 15-keto-dihydro-PGF(2 alpha)) lipid peroxidations were evaluated. Plasma levels of the endogenous antioxidants alpha- and gamma-tocopherols, were also analysed. RESULTS: Endotoxaemia increased plasma levels of 8-iso-PGF(2 alpha) (1st-4th h) and 15-keto-dihydro-PGF(2 alpha) (1st-4th h) significantly more in controls than in the propofol+endotoxin group. PaO(2) was significantly less affected by endotoxin in the propofol treated animals (2nd-4th h). Mean arterial pressure (4th-6th h) and systemic vascular resistance (6th h) were reduced significantly more by endotoxin among the propofol-treated animals. Vitamin E (alpha-tocopherol) increased in all animals, significantly more in the propofol+endotoxin group (1/2-6th h) than in the control group. CONCLUSIONS: Propofol reduced endotoxin-induced free radical mediated and cyclooxygenase catalysed lipid peroxidation significantly. The implication is that propofol counteracts endotoxin-induced deterioration of PaO(2).
Assuntos
Anestésicos Intravenosos/uso terapêutico , Dinoprosta/análogos & derivados , Endotoxemia/fisiopatologia , Infecções por Escherichia coli/fisiopatologia , Peroxidação de Lipídeos/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Propofol/análogos & derivados , Propofol/uso terapêutico , Choque Séptico/sangue , Choque Séptico/tratamento farmacológico , Vitamina E/fisiologia , Animais , Dinoprosta/sangue , F2-Isoprostanos/sangue , Inflamação/terapia , Radioimunoensaio , Suínos , Vitamina E/sangueRESUMO
BACKGROUND: The aims of this study were to investigate the anti-inflammatory effect and the effect on bone regeneration of hyaluronan in surgical and non-surgical groups. METHODS: In each of 15 individuals, 2 teeth with defects of similar character and magnitude in the upper or lower jaw were chosen. There were at least 2 teeth between the test and the control sites. In the surgical group, a bioabsorbable membrane was used for both test and control sites, and hyaluronan was placed in the intrabony pocket of the test site. In the non-surgical group, the periodontal pockets were scaled and hyaluronan was administered 3 times with an interval of 1 week in the test pockets. Alveolar bone height and bone healing patterns were analyzed using digital intraoral radiographs. Measurements of bone height were performed in the original digital black-and-white radiographs to obtain quantitative data on bone gain or loss. Bone healing patterns were studied with color-coded radiographs, using specially designed software in a personal computer with subsequent combinations of radiographs. Gingival crevicular fluid immunoglobulin (Ig)G, C3, and prostaglandin E2 (PGE2) responses; periodontal probing depth; bleeding on probing; and the presence of plaque were studied to evaluate the anti-inflammatory effect. Data were obtained at baseline before treatment, and at 2 weeks, and 1, 3, 6, and 12 months after treatment. RESULTS: For the surgical treatments, bone height was increased in the test group treated with hyaluronan (mean value 2.2%, corresponding to an average increase of approximately 0.5 mm) and reduced in the control group (mean value -1.8%, corresponding to an average decrease of approximately - 0.4 mm) (P<0.05) after 12 months. For the non-surgical treatments, bone height was reduced by a mean value of -1.1% (corresponding to an average decrease of approximately -0.25 mm) in the test group treated with hyaluronan and -3.3% (corresponding to an average decrease of approximately -0.75 mm) in the control group after 12 months (N.S.). According to the digital color-coded radiographs, the test sites in the surgical and non-surgical groups showed apposition of bone minerals. Immune responses showed no differences during the 12 months studied for the surgical and non-surgical sites. Mean periodontal probing depths were reduced between 2.5 mm and 4.1 mm in the surgical and non-surgical groups. CONCLUSIONS: The observed difference in bone height between test and control sites in the surgical group after 12 months was less than 1 mm, which was only detectable on radiographs. No statistical difference was found on radiographs in the non-surgical group, where a decrease in bone height was found for both groups after scaling. Probing depth reduction after the surgical treatment, as well as after scaling and root planing, was as expected. Hyaluronan in contact with bone and soft tissues had no influence on the immune system in this study. Further studies are needed to determine the extent to which hyaluronan can lead to clinically significant healing of periodontal lesions.
Assuntos
Adjuvantes Imunológicos/uso terapêutico , Perda do Osso Alveolar/tratamento farmacológico , Regeneração Óssea/efeitos dos fármacos , Ácido Hialurônico/uso terapêutico , Bolsa Periodontal/tratamento farmacológico , Cicatrização/efeitos dos fármacos , Implantes Absorvíveis , Adjuvantes Imunológicos/farmacologia , Adulto , Idoso , Aggregatibacter actinomycetemcomitans/isolamento & purificação , Perda do Osso Alveolar/diagnóstico por imagem , Perda do Osso Alveolar/cirurgia , Perda do Osso Alveolar/terapia , Complemento C3/análise , Índice de Placa Dentária , Raspagem Dentária , Dinoprostona/análise , Ensaio de Imunoadsorção Enzimática , Feminino , Líquido do Sulco Gengival/química , Líquido do Sulco Gengival/imunologia , Líquido do Sulco Gengival/microbiologia , Regeneração Tecidual Guiada Periodontal/métodos , Humanos , Ácido Hialurônico/farmacologia , Imunoglobulina G/análise , Masculino , Membranas Artificiais , Pessoa de Meia-Idade , Índice Periodontal , Radiografia Dentária Digital , Estatísticas não ParamétricasRESUMO
BACKGROUND: Development of topically active glucocorticosteroids with minimal systemic effects is paramount in improving therapy in inflammatory bowel disease. Our experimental model in the rat has proved useful for assessing topical versus systemic anti-inflammatory potency of glucocorticosteroids on the inflamed gut. METHODS: Experiments were performed on allergen-sensitized perfused rat ileum in vivo. Mucosal exudation of plasma, induced by local allergen perfusion, was measured as the appearance of circulating 125I-labelled albumin in the gut lumen. Experiments compared the anti-exudative effects of oral budesonide (0.1 mg/kg) with oral prednisolone (1, 3.3 or 10 mg/kg) and saline, given by oral gavage 24 h prior to allergen challenge, and of topical budesonide (3 x 10(-5) mol/L) with saline, administered in the perfusate 4 h prior to allergen challenge. Systemic glucocorticosteroid activity was assessed by weighing thymus glands after sacrifice. RESULTS: Allergen-induced plasma exudation was significantly reduced by oral budesonide, oral prednisolone (dose-dependently) and topically applied budesonide; topical budesonide was effective within 4 h. While prednisolone significantly reduced the relative thymus weight at both 3.3 and 10 mg/kg, budesonide given orally, 0.1 mg/kg, or topically, 3 x 10(-5) mol/L, had no significant effect. CONCLUSION: Budesonide, administered orally or topically, shows higher selectivity for the gut mucosa than prednisolone and produces local anti-inflammatory responses comparable to prednisolone, without the accompanying systemic effects.
Assuntos
Anti-Inflamatórios/administração & dosagem , Budesonida/administração & dosagem , Doenças Inflamatórias Intestinais/tratamento farmacológico , Mucosa Intestinal/efeitos dos fármacos , Prednisolona/administração & dosagem , Administração Oral , Administração Tópica , Animais , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Doenças Inflamatórias Intestinais/induzido quimicamente , Masculino , Ovalbumina/administração & dosagem , Ratos , Ratos Sprague-DawleyRESUMO
OBJECTIVE: The objective was to determine the long-term clinical outcome and the effects of treatment of patients with glutathione synthetase (GS) deficiency (n = 28). METHODS: The diagnosis was based on demonstration of a marked decrease in GS activity in erythrocytes or cultured fibroblasts in all patients and was supported by finding a decrease in erythrocyte or fibroblast glutathione, presence of 5-oxoprolinuria, or both. The treatment varied but usually included correction of acidosis and supplementation with vitamins C and/or E. RESULTS: Sixteen patients were severely affected with neurologic symptoms such as seizures and psychomotor retardation; 7 had died at the time of the study. None of the severely affected patients had been treated with both vitamins C and E from the neonatal period. No significant difference was found in GS activity between patients with or without neurologic symptoms or in erythrocyte or fibroblast glutathione levels. Five patients had recurrent bacterial infections. CONCLUSION: On the basis of clinical symptoms, patients with GS deficiency can be classified into 3 phenotypes: mild, moderate, and severe. Our results indicate that early supplementation with vitamins C and E may improve the long-term clinical outcome.
Assuntos
Glutationa Sintase/deficiência , Acidose/tratamento farmacológico , Adulto , Anemia Hemolítica/genética , Ácido Ascórbico/uso terapêutico , Criança , Pré-Escolar , Eritrócitos/enzimologia , Feminino , Fibroblastos/enzimologia , Genes Recessivos , Glutationa Sintase/genética , Humanos , Lactente , Recém-Nascido , Masculino , Mutação , Doenças do Sistema Nervoso/genética , Transtornos Psicomotores/genética , Fatores de Tempo , Vitamina E/uso terapêuticoRESUMO
Squalene is a cholesterol precursor, which stimulates the immune system nonspecifically. We demonstrate that one intradermal injection of this adjuvant lipid can induce joint-specific inflammation in arthritis-prone DA rats. Histopathological and immunohistochemical analyses revealed erosion of bone and cartilage, and that development of polyarthritis coincided with infiltration of alphabeta(+) T cells. Depletion of these cells with anti-alphabeta TcR monoclonal antibody (R73) resulted in complete recovery, whereas anti-CD8 and anti-gammadelta TcR injections were ineffective. The apparent dependence on CD4(+) T cells suggested a role for genes within the major histocompatibility complex (MHC), and this was concluded from comparative studies of MHC congenic rat strains, in which DA.1H rats were less susceptible than DA rats. Furthermore, LEW.1AV1 and PVG.1AV1 rats with MHC identical to DA rats were arthritis-resistant, demonstrating that non-MHC genes also determine susceptibility. Some of these genetic influences could be linked to previously described arthritis susceptibility loci in an F2 intercross between DA and LEW.1AV1 rats (ie, Cia3, Oia2 and Cia5). Interestingly, some F2 hybrid rats developed chronic arthritis, a phenotype not apparent in the parental inbred strains. Our demonstration that an autoadjuvant can trigger chronic, immune-mediated joint-specific inflammation may give clues to the pathogenesis of rheumatoid arthritis, and it raises new questions concerning the role of endogenous molecules with adjuvant properties in chronic inflammatory diseases.
Assuntos
Artrite Reumatoide/etiologia , Artrite/etiologia , Esqualeno/metabolismo , Linfócitos T/fisiologia , Animais , Formação de Anticorpos , Artrite/metabolismo , Artrite/patologia , Artrite/fisiopatologia , Artrite Reumatoide/patologia , Artrite Reumatoide/fisiopatologia , Doença Crônica , Colágeno/imunologia , Proteínas da Matriz Extracelular/imunologia , Predisposição Genética para Doença , Glicoproteínas/imunologia , Imunidade Celular , Imuno-Histoquímica , Interleucina-1/metabolismo , Articulações/metabolismo , Depleção Linfocítica , Complexo Principal de Histocompatibilidade/genética , Proteínas Matrilinas , Ratos , Ratos Endogâmicos/genética , Caracteres Sexuais , Fator de Necrose Tumoral alfa/metabolismoRESUMO
The present study was undertaken to investigate if subgingival administration of an EDTA gel has any adjunctive effect to subgingival and supragingival root debridement. The investigation was performed in one study center involving 6 clinical investigators and 91 patients. The patients were selected from 2 patient populations: 41 were included from a consecutive referral material on a voluntary basis, and 50 were included from a maintenance care material at the clinic. No significant differences were found between the EDTA-treated and control groups with respect to clinical attachment gain or probing pocket depth reduction. The referral patients showed a significant improvement of pocket depth and attachment gain compared to maintenance care patients at the clinic. In multiple regression analyses, it was found that patients with small attachment losses at baseline responded better to treatment than patients with severe periodontitis. Also, in multivariate analyses, referral patients responded better than maintenance patients when controlling for other predictors.
Assuntos
Quelantes/uso terapêutico , Ácido Edético/uso terapêutico , Periodontite/terapia , Aplainamento Radicular , Raiz Dentária/efeitos dos fármacos , Adulto , Doença Crônica , Feminino , Previsões , Géis , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Perda da Inserção Periodontal/prevenção & controle , Perda da Inserção Periodontal/terapia , Bolsa Periodontal/prevenção & controle , Bolsa Periodontal/terapia , Periodontite/classificação , Periodontite/prevenção & controle , Encaminhamento e Consulta , Análise de Regressão , Estatísticas não Paramétricas , Curetagem Subgengival , Resultado do TratamentoRESUMO
Coagulation and fibrinolysis are crucial in septic shock and inhibition of thrombin may be beneficial in this circumstance. Since porcine endotoxaemia has been found to replicate severe septic shock, a low molecular weight thrombin inhibitor, melagatran, was infused during the first 3 out of 6 h of endotoxaemia in pigs. Plasma creatinine (p <0.01) and urinary output (p <0.05) were less affected in the melagtran + endotoxin group (n=6) as compared to endotoxaemic controls (n=9). The left ventricular stroke work index, systemic vascular resistance index and oxygen extraction were all less affected (p <0.05) by endotoxin during the infusion of melagatran. The plasma concentration of melagatran declined with an apparent plasma half-life of 5 h as soon as the infusion was stopped. APTT, however, continued to increase after the infusion of melagatran had stopped and reached a maximum of 113 s at 5 h (baseline 17 s). APTT in endotoxaemic control pigs reached a maximum of 22 s. Thus, melagatran may counteract some consequences of endotoxaemia.
Assuntos
Endotoxemia/tratamento farmacológico , Fibrinolíticos/farmacologia , Glicina/análogos & derivados , Hemodinâmica/efeitos dos fármacos , Rim/efeitos dos fármacos , Choque Séptico/tratamento farmacológico , Trombina/antagonistas & inibidores , Animais , Azetidinas , Benzilaminas , Coagulação Sanguínea/efeitos dos fármacos , Creatinina/sangue , Diurese/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Endotoxemia/sangue , Endotoxemia/fisiopatologia , Feminino , Fibrinolíticos/uso terapêutico , Glicina/farmacologia , Glicina/uso terapêutico , Meia-Vida , Rim/fisiopatologia , Masculino , Consumo de Oxigênio/efeitos dos fármacos , Tempo de Tromboplastina Parcial , Contagem de Plaquetas/efeitos dos fármacos , SuínosRESUMO
We have reported the cloning from mouse genomic DNA of a fragment encoding a G-protein-coupled receptor related to the receptor for the blood clotting enzyme thrombin. Like the thrombin receptor this receptor is activated by proteolytic cleavage of its extracellular amino terminus. Because the physiological agonist at the receptor was unknown, we provisionally named it proteinase-activated receptor 2 (PAR-2). Here we present a PAR-2 cDNA of 2729 nucleotides that differs from the published genomic sequence at the 5' end, including a part of the protein coding region. The differences do not affect the peptide sequence of the activating proteinase cleavage site proper, but may include amino acid residues important for enzyme-substrate recognition. Analysis of the PAR-2 gene structure showed that the cDNA 5' end is derived from a separate exon located about 10 kilobases away from the 3' exon. Results from a primer extension experiment indicate that transcription starts at a unique site around nucleotide -203 respective to the translation initiation ATG. Chinese hamster ovary cells transfected with either the PAR-2 cDNA or a construct made from the published PAR-2 genomic sequence responded with intracellular calcium mobilization to stimulation with 1 nM trypsin, 10 microM PAR-2-activating peptide (SLIGRL), or 1 microM thrombin receptor-activating peptide (SFLLRN). Untransfected cells responded only to stimulation with thrombin receptor activating peptide. Only transcripts corresponding to the PAR-2 cDNA could be detected in three mouse tissues examined.
Assuntos
Camundongos/genética , Receptores de Superfície Celular/biossíntese , Receptores de Superfície Celular/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Células CHO , Cálcio/metabolismo , Clonagem Molecular , Cricetinae , Primers do DNA , DNA Complementar , Proteínas de Ligação ao GTP/metabolismo , Mucosa Gástrica/metabolismo , Expressão Gênica , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Receptor PAR-2 , Receptores de Superfície Celular/metabolismo , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/metabolismo , Mapeamento por Restrição , Transcrição Gênica , TransfecçãoAssuntos
Aconselhamento , Serviços de Saúde Materna , Feminino , Humanos , Tocologia , Gravidez , SuéciaRESUMO
In a therapeutic trial, the effect of short-term low-dosage N-acetylcysteine supplementation on glutathione metabolism was investigated in two patients with hereditary glutathione deficiency (5-oxoprolinuria). Clinical and neurophysiological examinations of the patients indicated progressive neurological damage. The pretreatment concentrations of total and free glutathione in leukocytes were 15-20% of normal, whereas the corresponding gamma-glutamylcysteine levels were increased. In plasma, the glutathione concentrations were similarly decreased, but no gamma-glutamylcysteine was detected. Total glutathione in erythrocytes was markedly decreased. Low urinary excretion of cysteinylglycine, cyst(e)ine, taurine, N-acetylcysteine, mercaptolactate and mercaptoacetate and reduced leukocyte taurine levels constituted additional evidence of decreased intracellular availability of cysteine, i.e. glutathione. Oral supplementation with N-acetylcysteine (5 mg/kg x 3/day) had no effect on acid-base balance, erythrocyte glutathione levels or 5-oxoproline concentrations in plasma and urine. In leukocytes, the glutathione concentrations were increased by 20-30%, whereas the gamma-glutamylcysteine levels were essentially unaltered. In parallel, the urinary excretion of cysteinylglycine was increased and the leukocyte levels and urinary outputs of sulphur amino acids were restored. No side-effects of the treatment were noted. The results indicate that N-acetylcysteine may be of value in increasing the low intracellular glutathione concentrations and cysteine availability in patients with hereditary glutathione synthetase deficiency.
Assuntos
Acetilcisteína/uso terapêutico , Glutationa Sintase/deficiência , Peptídeo Sintases/deficiência , Adolescente , Aminoácidos Sulfúricos/sangue , Aminoácidos Sulfúricos/urina , Feminino , Glutationa/sangue , Glutationa/urina , Glutationa Sintase/genética , Humanos , Leucócitos/efeitos dos fármacos , Leucócitos/metabolismo , Ácido Pirrolidonocarboxílico/sangue , Ácido Pirrolidonocarboxílico/urinaRESUMO
A monoclonal antibody, K46M (IgM kappa), obtained after immunization with leucoagglutinin (La)-reactive T-cell surface components, stimulated human lymphocytes to proliferate. It induced maximal proliferation at greater than 20 micrograms IgM/ml after 3-4 days of culture. Cells stimulated by K46M produced interleukin 2 (IL-2) and gamma interferon (IFN-gamma) and expressed receptors for IL-2 and transferrin. The majority of the activated cells were phenotypically T cells as defined by monoclonal antibodies against CD3 and CD2, and an increase in the K46M-positive cells was also observed during the activation period. K46M-activated cells display major histocompatibility complex (MHC)-unrestricted cytotoxicity against several cultured target cells. The frequencies of the cytotoxic and of the proliferative precursor cells were determined using a limiting dilution assay. K46M seems to activate a larger fraction of cytotoxic precursor cells against Molt 4 than against K562, but the statistical significance of these observations requires further exploration. Both K46M or La activated 40% of PBL to proliferate, whereas 70% of PBL were induced by OKT3. However, the frequency of K46M-activated cells was 40% only when the lymphocytes were plated at low cell densities, i.e. less than 0.5 cells per well. At higher densities an inhibition of proliferation was seen that resulted in a biphasic response curve, indicating that the activation of PBL by K46M was not a single hit event. This was not found with either La or OKT3. Whether K46M, in contrast to OKT3 and La, activates a subpopulation with suppressor activity remains to be established.
Assuntos
Anticorpos Monoclonais/fisiologia , Antígenos de Superfície/imunologia , Contagem de Leucócitos , Ativação Linfocitária , Fito-Hemaglutininas/imunologia , Linfócitos T/imunologia , Animais , Testes Imunológicos de Citotoxicidade , Fabaceae , Humanos , Camundongos , Mitógenos/fisiologia , Lectinas de Plantas , Plantas Medicinais , Células-Tronco/imunologia , Linfócitos T Citotóxicos/imunologiaRESUMO
The toxic, irritative, and sensitizing effects of topically applied sodium lauryl sulfate (SLS), dithranol triacetate (DTA), nonanoic acid in methyl- or propyl ester (NAM, NAP) in the buccal mucosa were investigated in a Sprague-Dawley rat model. Semi-quantitative evaluations of cellular infiltrates were performed in routine histologic preparations. The toxic potential was tested with 2% and 0.2% solutions. All substances, except 0.2% SLS, caused an increased cellularity, mainly of a mononuclear cell type. The low dose of NAM induced stronger inflammatory reactions than the high dose. Repeated applications of 2% solutions decreased the response compared to one application, except for NAM, where a clear irritative potential was observed. Pre-exposure of dorsal skin prior to buccal painting resulted in an enhanced reaction to NAM and NAP, whereas no sensitizing capacity was noted in SLS or DTA in this model.
Assuntos
Antralina/análogos & derivados , Anti-Infecciosos Locais/efeitos adversos , Ácidos Graxos/efeitos adversos , Irritantes , Dodecilsulfato de Sódio/efeitos adversos , Estomatite/induzido quimicamente , Alérgenos , Animais , Antralina/administração & dosagem , Antralina/efeitos adversos , Anti-Infecciosos Locais/administração & dosagem , Ácidos Graxos/administração & dosagem , Masculino , Mucosa Bucal/efeitos dos fármacos , Mucosa Bucal/patologia , Ratos , Ratos Endogâmicos , Dodecilsulfato de Sódio/administração & dosagem , Estomatite/patologiaRESUMO
In order to evaluate further the possibility that transient hypothyroidism and hyperthyrotropinemia in newborn infants could result from a state of relative iodine deficiency, the urinary concentration of iodine, used as an index of the dietary intake of iodine was determined in casual urine samples collected in 1,076 full-term infants aged 3-6 days in 16 cities in 10 different European countries and in Toronto, Canada. In addition, the results obtained by programs of systematic neonatal screening for congenital hypothyroidism in the same areas were compared. There were marked regional differences in iodine nutrition during the neonatal period in Europe (median urinary iodine: 16.2 micrograms/dl in Rotterdam, the Netherlands, and 1.1 micrograms/dl in Freiburg, FRG. A low iodine supply in newborn populations was accompanied by, and probably explained, an elevated frequency of transient disorders of thyroid function in young infants. Iodine prophylaxis is urgently needed in some European countries not only for the prevention of goiter, but mostly for the prevention of impairment of thyroid function during the critical period of brain development.